Luoxin Pharmaceuticals Group Stock Co., Ltd. engages in the research and development, production, and sales of pharmaceutical products in China. The company provides anti-infective active pharmaceutical ingredients(APIs), antiviral APIs, respiratory and digestive system, nervous and endocrine system, cardiovascular system, oncology, and anti-allergic APIs and intermediates, as well as antipyretic, analgesics, and anti-inflammatory APIs and intermediates. It also offers health care services. Luoxin Pharmaceuticals Group Stock Co., Ltd. was formerly known as Zhejiang Doyin Pump Industry Co., Ltd. and changed its name to Luoxin Pharmaceuticals Group Stock Co., Ltd. in April 2020. The company was founded in 1998 and is based in Linyi, China.
Research context
Luoxin Pharmaceuticals Group Stock Co., Ltd appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 7 months ago
Luoxin Pharmaceuticals Group Stock Co., Ltd is currently in a long term downtrend where the price is trading 11.2% below its 200 day moving average.
From a valuation standpoint, the stock is 78.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.1.
Luoxin Pharmaceuticals Group Stock Co., Ltd's total revenue rose by 535.3% to $2B since the same quarter in the previous year.
Its net income has increased by 7587.9% to $129M since the same quarter in the previous year.
Finally, its free cash flow fell by 336.4% to $-184M since the same quarter in the previous year.
Based on the above factors, Luoxin Pharmaceuticals Group Stock Co., Ltd gets an overall score of 3/5.